Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Abstract Background and objective Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-025-02610-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231366882426880 |
|---|---|
| author | Ivette Cruz-Bautista Yuscely Flores-Jurado Guillermo Roa-Álvarez Mariana Salas-Aldana Daniel Benjamin Elías-Lopez Ricardo Federico Hernández-Franco Sandra Rosales-Uvera Arsenio Vargas-Vázquez Raymundo Valdez-Echeverría Sonia Luna del Villar Velasco Liliana Muñoz-Hernández Roopa Mehta Mario Morales-Esponda Misael Aguilar-Panduro Guillermo Chan-Puga Adrián Soto Mota Carlos Alberto Aguilar-Salinas |
| author_facet | Ivette Cruz-Bautista Yuscely Flores-Jurado Guillermo Roa-Álvarez Mariana Salas-Aldana Daniel Benjamin Elías-Lopez Ricardo Federico Hernández-Franco Sandra Rosales-Uvera Arsenio Vargas-Vázquez Raymundo Valdez-Echeverría Sonia Luna del Villar Velasco Liliana Muñoz-Hernández Roopa Mehta Mario Morales-Esponda Misael Aguilar-Panduro Guillermo Chan-Puga Adrián Soto Mota Carlos Alberto Aguilar-Salinas |
| author_sort | Ivette Cruz-Bautista |
| collection | DOAJ |
| description | Abstract Background and objective Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Methods Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Results Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Conclusions Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk. |
| format | Article |
| id | doaj-art-96b3a741129d4ba596c5ab3e88a043c9 |
| institution | OA Journals |
| issn | 1476-511X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj-art-96b3a741129d4ba596c5ab3e88a043c92025-08-20T02:03:32ZengBMCLipids in Health and Disease1476-511X2025-05-0124111210.1186/s12944-025-02610-wLipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institutionIvette Cruz-Bautista0Yuscely Flores-Jurado1Guillermo Roa-Álvarez2Mariana Salas-Aldana3Daniel Benjamin Elías-Lopez4Ricardo Federico Hernández-Franco5Sandra Rosales-Uvera6Arsenio Vargas-Vázquez7Raymundo Valdez-Echeverría8Sonia Luna del Villar Velasco9Liliana Muñoz-Hernández10Roopa Mehta11Mario Morales-Esponda12Misael Aguilar-Panduro13Guillermo Chan-Puga14Adrián Soto Mota15Carlos Alberto Aguilar-Salinas16Unidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Radiología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Laboratorio Central, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Laboratorio Central, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránDepartamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránUnidad de Investigación en Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránAbstract Background and objective Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Methods Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Results Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Conclusions Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.https://doi.org/10.1186/s12944-025-02610-wLp(a)AwarenessMexican cohortClinical interventions |
| spellingShingle | Ivette Cruz-Bautista Yuscely Flores-Jurado Guillermo Roa-Álvarez Mariana Salas-Aldana Daniel Benjamin Elías-Lopez Ricardo Federico Hernández-Franco Sandra Rosales-Uvera Arsenio Vargas-Vázquez Raymundo Valdez-Echeverría Sonia Luna del Villar Velasco Liliana Muñoz-Hernández Roopa Mehta Mario Morales-Esponda Misael Aguilar-Panduro Guillermo Chan-Puga Adrián Soto Mota Carlos Alberto Aguilar-Salinas Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution Lipids in Health and Disease Lp(a) Awareness Mexican cohort Clinical interventions |
| title | Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution |
| title_full | Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution |
| title_fullStr | Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution |
| title_full_unstemmed | Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution |
| title_short | Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution |
| title_sort | lipoprotein a levels and clinical decision making data from a mexican cohort at a tertiary medical institution |
| topic | Lp(a) Awareness Mexican cohort Clinical interventions |
| url | https://doi.org/10.1186/s12944-025-02610-w |
| work_keys_str_mv | AT ivettecruzbautista lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT yuscelyfloresjurado lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT guillermoroaalvarez lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT marianasalasaldana lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT danielbenjamineliaslopez lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT ricardofedericohernandezfranco lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT sandrarosalesuvera lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT arseniovargasvazquez lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT raymundovaldezecheverria lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT sonialunadelvillarvelasco lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT lilianamunozhernandez lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT roopamehta lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT mariomoralesesponda lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT misaelaguilarpanduro lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT guillermochanpuga lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT adriansotomota lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution AT carlosalbertoaguilarsalinas lipoproteinalevelsandclinicaldecisionmakingdatafromamexicancohortatatertiarymedicalinstitution |